X4 Pharmaceuticals (XFOR) Change in Account Payables (2017 - 2025)
X4 Pharmaceuticals (XFOR) reported Change in Account Payables of $642000.0 for Q4 2025, up 723.08% on a YoY basis from $78000.0 in Q4 2024, and up 124.19% quarter-over-quarter from -$2.7 million in Q3 2025.
X4 Pharmaceuticals (XFOR) Change in Account Payables (2017 - 2025) Analysis & Trends
X4 Pharmaceuticals has reported Change in Account Payables for 9 years, with the latest figure at $642000.0 in Q4 2025.
- For the quarter ending Q4 2025, Change in Account Payables rose 723.08% year-over-year to $642000.0; the trailing twelve-month figure through Dec 2025 stood at -$3.0 million (down 941.61% YoY), and the FY2025 full-year result was -$3.0 million, down 941.61% from the prior year.
- Change in Account Payables for Q4 2025 stood at $642000.0, up from -$2.7 million in the prior quarter.
- The five-year high for Change in Account Payables was $3.9 million in Q4 2022, with the low at -$3.4 million in Q2 2025.
- Historically, Change in Account Payables has averaged $128000.0 across 5 years, with a median of $41000.0 in 2024.
- Annual changes were most pronounced in 2022 — Change in Account Payables plunged 3000.0% — and 2025, when it soared 61800.0%.
- X4 Pharmaceuticals' Change in Account Payables stood at $1.9 million in 2021, then surged by 109.89% to $3.9 million in 2022, then slumped by 79.31% to $808000.0 in 2023, then plunged by 90.35% to $78000.0 in 2024, then soared by 723.08% to $642000.0 in 2025.
- The last three Change in Account Payables figures came in at $642000.0 (Q4 2025), -$2.7 million (Q3 2025), and -$3.4 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | -3.26 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 35.60 Mn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | -9.42 Mn |
| 10 | X4 Pharmaceuticals | 166.63 Mn | 166.63 Mn | 2.20 Mn | 642,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 642,000.00 |
| Dec 31, 2025 | 642,000.00 |
| Sep 30, 2025 | -2.65 Mn |
| Sep 30, 2025 | -2.65 Mn |
| Jun 30, 2025 | -3.44 Mn |
| Jun 30, 2025 | -3.44 Mn |
| Mar 31, 2025 | 2.48 Mn |
| Mar 31, 2025 | 2.48 Mn |
| Dec 31, 2024 | 78,000.00 |
| Dec 31, 2024 | 78,000.00 |
| Sep 30, 2024 | 580,000.00 |
| Sep 30, 2024 | 580,000.00 |
| Jun 30, 2024 | -948,000.00 |
| Jun 30, 2024 | -948,000.00 |
| Mar 31, 2024 | 4,000.00 |
| Mar 31, 2024 | 4,000.00 |
| Dec 31, 2023 | 808,000.00 |
| Dec 31, 2023 | 808,000.00 |
| Sep 30, 2023 | 3.24 Mn |
| Sep 30, 2023 | 3.24 Mn |